Literature DB >> 29398356

A Subpopulation of Striatal Neurons Mediates Levodopa-Induced Dyskinesia.

Allison E Girasole1, Matthew Y Lum2, Diane Nathaniel2, Chloe J Bair-Marshall2, Casey J Guenthner3, Liqun Luo3, Anatol C Kreitzer4, Alexandra B Nelson5.   

Abstract

Parkinson's disease is characterized by the progressive loss of midbrain dopamine neurons. Dopamine replacement therapy with levodopa alleviates parkinsonian motor symptoms but is complicated by the development of involuntary movements, termed levodopa-induced dyskinesia (LID). Aberrant activity in the striatum has been hypothesized to cause LID. Here, to establish a direct link between striatal activity and dyskinesia, we combine optogenetics and a method to manipulate dyskinesia-associated neurons, targeted recombination in active populations (TRAP). We find that TRAPed cells are a stable subset of sensorimotor striatal neurons, predominantly from the direct pathway, and that reactivation of TRAPed striatal neurons causes dyskinesia in the absence of levodopa. Inhibition of TRAPed cells, but not a nonspecific subset of direct pathway neurons, ameliorates LID. These results establish that a distinct subset of striatal neurons is causally involved in LID and indicate that successful therapeutic strategies for treating LID may require targeting functionally selective neuronal subtypes.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Basal ganglia; Parkinson’s disease; direct pathway; dopamine; levodopa-induced dyskinesia; optogenetics

Mesh:

Substances:

Year:  2018        PMID: 29398356      PMCID: PMC6233726          DOI: 10.1016/j.neuron.2018.01.017

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  44 in total

1.  Accuracy of tetrode spike separation as determined by simultaneous intracellular and extracellular measurements.

Authors:  K D Harris; D A Henze; J Csicsvari; H Hirase; G Buzsáki
Journal:  J Neurophysiol       Date:  2000-07       Impact factor: 2.714

2.  Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements.

Authors:  Xuebing Cao; Toru Yasuda; Subramaniam Uthayathas; Ray L Watts; M Maral Mouradian; Hideki Mochizuki; Stella M Papa
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

3.  Site-specific action of L-3,4-dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic L-3,4-dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats.

Authors:  K Buck; P Voehringer; B Ferger
Journal:  Neuroscience       Date:  2009-12-22       Impact factor: 3.590

4.  Altered somatosensory cortex neuronal activity in a rat model of Parkinson's disease and levodopa-induced dyskinesias.

Authors:  Mesbah Alam; Regina Rumpel; Xingxing Jin; Christof von Wrangel; Sarah K Tschirner; Joachim K Krauss; Claudia Grothe; Andreas Ratzka; Kerstin Schwabe
Journal:  Exp Neurol       Date:  2017-04-23       Impact factor: 5.330

Review 5.  Dopaminergic modulation of striatal neurons, circuits, and assemblies.

Authors:  D J Surmeier; L Carrillo-Reid; J Bargas
Journal:  Neuroscience       Date:  2011-08-27       Impact factor: 3.590

6.  Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.

Authors:  Xiomara A Perez; Danhui Zhang; Tanuja Bordia; Maryka Quik
Journal:  Mov Disord       Date:  2017-03-03       Impact factor: 10.338

7.  Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy.

Authors:  Cristina Alcacer; Laura Andreoli; Irene Sebastianutto; Johan Jakobsson; Tim Fieblinger; Maria Angela Cenci
Journal:  J Clin Invest       Date:  2017-01-23       Impact factor: 14.808

8.  Selective activation of striatal fast-spiking interneurons during choice execution.

Authors:  Gregory J Gage; Colin R Stoetzner; Alexander B Wiltschko; Joshua D Berke
Journal:  Neuron       Date:  2010-08-12       Impact factor: 17.173

9.  Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease.

Authors:  Vincenza Bagetta; Carmelo Sgobio; Valentina Pendolino; Giulia Del Papa; Alessandro Tozzi; Veronica Ghiglieri; Carmela Giampà; Elisa Zianni; Fabrizio Gardoni; Paolo Calabresi; Barbara Picconi
Journal:  J Neurosci       Date:  2012-12-05       Impact factor: 6.167

10.  M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.

Authors:  Weixing Shen; Joshua L Plotkin; Veronica Francardo; Wai Kin D Ko; Zhong Xie; Qin Li; Tim Fieblinger; Jürgen Wess; Richard R Neubig; Craig W Lindsley; P Jeffrey Conn; Paul Greengard; Erwan Bezard; M Angela Cenci; D James Surmeier
Journal:  Neuron       Date:  2015-11-18       Impact factor: 17.173

View more
  30 in total

Review 1.  Dopaminergic modulation of striatal function and Parkinson's disease.

Authors:  Shenyu Zhai; Weixing Shen; Steven M Graves; D James Surmeier
Journal:  J Neural Transm (Vienna)       Date:  2019-04-01       Impact factor: 3.575

2.  Optostimulation of striatonigral terminals in substantia nigra induces dyskinesia that increases after L-DOPA in a mouse model of Parkinson's disease.

Authors:  Ettel Keifman; Irene Ruiz-DeDiego; Diego Esteban Pafundo; Rodrigo Manuel Paz; Oscar Solís; Mario Gustavo Murer; Rosario Moratalla
Journal:  Br J Pharmacol       Date:  2019-05-21       Impact factor: 8.739

3.  Striatal Direct Pathway Targets Npas1+ Pallidal Neurons.

Authors:  Qiaoling Cui; Xixun Du; Isaac Y M Chang; Arin Pamukcu; Varoth Lilascharoen; Brianna L Berceau; Daniela García; Darius Hong; Uree Chon; Ahana Narayanan; Yongsoo Kim; Byung Kook Lim; C Savio Chan
Journal:  J Neurosci       Date:  2021-03-17       Impact factor: 6.167

4.  Abnormal Cortico-Basal Ganglia Neurotransmission in a Mouse Model of l-DOPA-Induced Dyskinesia.

Authors:  Indriani Dwi Wahyu; Satomi Chiken; Taku Hasegawa; Hiromi Sano; Atsushi Nambu
Journal:  J Neurosci       Date:  2021-02-09       Impact factor: 6.167

5.  Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine.

Authors:  Weixing Shen; Wenjie Ren; Shenyu Zhai; Ben Yang; Carlos G Vanoye; Ananya Mitra; Alfred L George; D James Surmeier
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

6.  Complementary Genetic Targeting and Monosynaptic Input Mapping Reveal Recruitment and Refinement of Distributed Corticostriatal Ensembles by Cocaine.

Authors:  Nicholas R Wall; Peter A Neumann; Kevin T Beier; Ava K Mokhtari; Liqun Luo; Robert C Malenka
Journal:  Neuron       Date:  2019-11-20       Impact factor: 17.173

7.  Translating Insights From Optogenetics To Therapies For Parkinson's Disease.

Authors:  Aryn H Gittis; Eric A Yttri
Journal:  Curr Opin Biomed Eng       Date:  2018-09-12

Review 8.  A competitive model for striatal action selection.

Authors:  S Bariselli; W C Fobbs; M C Creed; A V Kravitz
Journal:  Brain Res       Date:  2018-10-06       Impact factor: 3.252

9.  Subregion-Specific Regulation of Dopamine D1 Receptor Signaling in the Striatum: Implication for L-DOPA-Induced Dyskinesia.

Authors:  Keita Sugiyama; Mahomi Kuroiwa; Takahide Shuto; Yoshinori N Ohnishi; Yukie Kawahara; Yuta Miyamoto; Takaichi Fukuda; Akinori Nishi
Journal:  J Neurosci       Date:  2021-06-15       Impact factor: 6.167

10.  Precisely timed dopamine signals establish distinct kinematic representations of skilled movements.

Authors:  Alexandra Bova; Matt Gaidica; Amy Hurst; Yoshiko Iwai; Julia Hunter; Daniel K Leventhal
Journal:  Elife       Date:  2020-11-27       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.